Literature DB >> 6326253

Multi-modality treatment in males with advanced malignant germ cell tumours. II. Experience with surgery and radiotherapy following cis-platinum-based chemotherapy.

S D Fosså, O Klepp, S Ous, H Lien, J T Stenwig, V Abeler, G Eliassen, H Høst.   

Abstract

After chemotherapy with cis-platinum, vinblastine and bleomycin, 33 surgical procedures were performed in 29 patients with advanced malignant germ-cell tumours. The tumour masses could be completely resected macroscopically in 26 patients. Histology of the operation specimens showed fibrosis/necrosis (9 specimens), mature teratome (13 specimens) and vital malignant tumour (11 specimens). Patients with fibrosis/necrosis or completely resected mature teratoma had an excellent prognosis, whereas only 5 of the 11 patients with vital malignant tumour survived in spite of second-line treatment with chemotherapy/radiotherapy. Preoperatively elevated serum levels of AFP, beta-HCG and/or LDH indicated the presence of residual vital malignant germ cell tumour. Eight of 14 patients were rendered tumour-free by radiotherapy given as second- or third-line treatment. In general, tumour masses, remaining after cis-platinum-based induction chemotherapy should be resected as completely as possible even in the case of mature teratoma or fibrosis/necrosis. Radiotherapy should be considered as second- and third-line treatment in selected patients.

Entities:  

Mesh:

Year:  1984        PMID: 6326253     DOI: 10.3109/00365598409182159

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  2 in total

1.  Germ cell testicular tumours with lung metastases: chemotherapy and surgical treatment.

Authors:  S Cărsky; D Ondrus; M Schnorrer; M Májek
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection.

Authors:  K D Jacobsen; S Ous; H Waehre; H Trasti; A E Stenwig; H H Lien; N Aass; S D Fosså
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.